Previous Article | Next Article ![]()
Clinical Microbiology Reviews, April 2008, p. 274-290, Vol. 21, No. 2
0893-8512/08/$08.00+0 doi:10.1128/CMR.00045-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
GlaxoSmithKline, London, United Kingdom,1 Program in Infectious Diseases and Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center,2 Children's Hospital and Regional Medical Center,3 University of Washington, Seattle, Washington4
Summary: Though several antivirals have been developed and marketed to treat influenza virus infections, the development of antiviral agents with clinical activity against other respiratory viruses has been more problematic. Here we review the epidemiology of respiratory viral infections in immunocompetent and immunocompromised hosts, examine the evidence surrounding the currently available antivirals for respiratory viral infections other than influenza, highlight those that are in the pipeline, and discuss the hurdles for development of such agents.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»